BDBM230091 US10106559, Example 14::US10435415, Example 14::US9334290, 13::US9334290, 14::US9850258, Example 14

SMILES Cc1c(cccc1-n1c(=O)[nH]c2c(F)cccc2c1=O)-c1c(Cl)cc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O

InChI Key InChIKey=YKIOXAGXNAHDOG-UHFFFAOYSA-N

Data  20 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 20 hits for monomerid = 230091   

TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  2.90nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  300nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  570nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  300nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  260nMAssay Description:Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  1.60nMAssay Description:Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  260nMAssay Description:Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  1.60nMAssay Description:Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  2.90nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  570nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  1.20nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  300nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  2.90nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  570nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  1.20nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  300nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  2.90nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  570nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  1.20nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230091(US10106559, Example 14 | US10435415, Example 14 | ...)
Affinity DataIC50:  1.20nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent